Based on this, there is no clear evidence to recommend the combination of platinum-based chemotherapy plus PD-1/PD-L1 inhibitor in patients with PS 2 and whose tumor is positive for PD-L1 ≥ 50%. This evidence concerns the gene CD274 and neoplasm.